Tofacitinib, soluble in warmed DMSO and insoluble in water and ethanol, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, JAK3, Lck, and Rock-II.
Tofacitinib can be used to investigate its JAK1/3 inhibition for research in rheumatoid arthritis and other inflammatory diseases.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.